MRTX1719 is an inhibitor of the PRMT5/MTA complex and recently entered clinical trials for the treatment of MTAP-deleted cancers. MRTX1719 is a class 3 atropisomeric compound that requires a chiral synthesis or a chiral separation step in its preparation. Here, we report the SAR and medicinal chemistry design strategy, supported by structural insights from X-ray crystallography, to discover a class 1 atropisomeric compound from the same series that does not require a chiral synthesis or a chiral separation step in its preparation.
Keywords: Atropisomer; MRTX1719; MTA; MTAP; PRMT5; Structure-based drug design.
Copyright © 2022 Mirati Therapeutics, Inc. Published by Elsevier Ltd.. All rights reserved.